Regenxbio (RGNX) Research & Development (2014 - 2026)
Regenxbio (RGNX) posted quarterly Research & Development of $59.6 million for Q4 2025, up 18.32% year-over-year from $50.4 million in Q4 2024, and up 6.26% quarter-over-quarter from $56.1 million in Q3 2025.
Regenxbio (RGNX) Research & Development (2014 - 2026) Analysis & Trends
Regenxbio's Research & Development history runs 12 years deep, the most recent figure standing at $59.6 million for Q4 2025.
- In Q4 2025, Research & Development rose 18.32% year-over-year to $59.6 million; the TTM figure through Dec 2025 stood at $228.3 million (up 9.48% YoY), while the FY2025 annual figure was $228.3 million, up 9.48% from the prior year.
- Research & Development for Q4 2025 stood at $59.6 million, up from $56.1 million in the prior quarter.
- The five-year high for Research & Development was $63.3 million in Q3 2022, with the low at $39.7 million in Q1 2021.
- The 5-year median for Research & Development is $55.7 million (2022), against an average of $54.6 million.
- The sharpest annual moves came in 2022 and 2024: Research & Development surged 40.04% in 2022, then slipped 18.4% in 2024.
- Regenxbio's Research & Development stood at $48.0 million in 2021, then jumped by 30.28% to $62.5 million in 2022, then retreated by 10.92% to $55.7 million in 2023, then slipped by 9.52% to $50.4 million in 2024, then gained by 18.32% to $59.6 million in 2025.
- Business Quant data shows RGNX's Research & Development at $59.6 million in Q4 2025, $56.1 million in Q3 2025, and $59.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | 56.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.09 Mn |
| Dec 31, 2025 | 59.61 Mn |
| Sep 30, 2025 | 56.10 Mn |
| Jun 30, 2025 | 59.50 Mn |
| Mar 31, 2025 | 53.09 Mn |
| Dec 31, 2024 | 50.38 Mn |
| Sep 30, 2024 | 54.43 Mn |
| Jun 30, 2024 | 48.87 Mn |
| Mar 31, 2024 | 54.84 Mn |
| Dec 31, 2023 | 55.68 Mn |
| Sep 30, 2023 | 58.18 Mn |
| Jun 30, 2023 | 59.89 Mn |
| Mar 31, 2023 | 58.52 Mn |
| Dec 31, 2022 | 62.51 Mn |
| Sep 30, 2022 | 63.31 Mn |
| Jun 30, 2022 | 61.01 Mn |
| Mar 31, 2022 | 55.63 Mn |
| Dec 31, 2021 | 47.98 Mn |
| Sep 30, 2021 | 47.86 Mn |
| Jun 30, 2021 | 45.88 Mn |